The RANKL-RANK signaling pathway plays a key role in the development of osteoclasts and the regulation of the immune system. This signaling pathway not only works as a major mediator of osteoclast activation, formation and inventory, but also functions in breast, brain and lymph nodes. Disorders of the RANKL-RANK signaling pathway can lead to a variety of diseases, including postmenopausal osteoporosis, rheumatoid arthritis (RA), bone tumors, and certain bone metastatic tumors. Creative BioMart Biomarker is capable to provide our customers with superior RANKL detection service, various detection methods ensuring high sensitivity for detecting biomarkers in different samples with different concentrations.
Introduction
Receptor activator for nuclear factor kappa-B ligand (RANKL) is a member of the TNF receptor superfamily and is produced by osteocytes, pre-osteoblasts and endothelial cells. In the presence of macrophage colony-stimulating factor, RANKL binds to its receptor RANK, resulting in increased osteoclast formation and activity. In the late 1990s, it was discovered that the nuclear factor κB receptor activator ligand (RANKL) and its ligand (RANK) can induce osteoclastogenesis, while osteoprotegerin (OPG) acts as a soluble molecular decoy. The RANKL-RANK signaling pathway plays a key role in the development of osteoclasts and the regulation of the immune system. Stimulated by parathyroid (PYD) hormone, vitamin D or prostaglandin 2, osteoblasts and osteocytes present RANKL to osteoblast progenitor cells. OPG inhibits RANK signaling by preventing interactions between RANKL-RANK. Upon binding to RANKL, the RANK receptor undergoes trimerization and recruits a TRAF6 adaptor molecule that conjugates RANK to a variety of signaling pathways. c-Src activates anti-apoptotic signals via Akt/protein kinase B. Activation of MAPK induces translocation of c-Fos and c-Jun to the nucleus. The nuclear translocation of NF-κB up-regulate c-Fos, and the c-Fos and Ca2+-regulated NFATc1 complex initiates the genetic program required for osteoclast formation and maturation.
Figure 1. RANKL-RANK signaling.
Application of RANKL
- Serum, urine RANKL levels can be used as biomarkers to predict fracture risk and monitor the response to osteoporosis treatment.
Our Advantages
- Accept a wide range of sample types (serum, urine)
- Ensure high sensitivity for detecting RANKL in different samples
- Ensure high accuracy and repeatable RANKL detection
- Ensure a wide kinetic range to detect samples of different concentrations
- Short experimental period
Workflow of RANKL Detection at Creative BioMart Biomarker
Creative BioMart Biomarker strictly controls each specific experimental step in the RANKL detection procedure to ensure high sensitivity, high accuracy and repeatable RANKL detection.
Please feel free to contact us if you would like to know more about RANKL detection. At Creative BioMart Biomarker, we not only provide high-quality RANKL detection service, but also provide detection services for other biomarkers. Additionally, our experts can also provide and help design the best solution according to your specific requirements.
References:
- Hlaing, T.T.; Compston, J.E. Biochemical markers of bone turnover – uses and limitations. Annals of Clinical Biochemistry. 2014, 51(2):189-202.
- Liu, W.; Zhang X.L. Receptor activator of nuclear factor‑κB ligand (RANKL)/RANK/osteoprotegerin system in bone and other tissues. Molcule Medicine Reports. 2015, 11: 3212-3218.
- Nagy, V.; Penninger J.M. The RANKL-RANK story. Gerontology. 2015, 61:534-542.
